UNSPSC 51363401: Acecarbromal

This classification denotes a sedative and hypnotic with the molecular formula C9H15BrN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E47C56IGOY, chemically known as urea, 1-acetyl-3-(2-bromo-2-ethylbutyryl)- but generally known as acecarbromal, which bears US NIH Compound Identifier 6489. European Medicines Agency schedules Acecarbromal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05198MIG. The term ACECARBROMAL is an International Non-Proprietary Name.

UNSPSC 51363401 Acecarbromal is a Commodity code that in recent state and local procurement activity designates pharmaceutical products and drug-related systems rather than acecarbromal specifically. Seminole County, Florida procures naloxone and drug deactivation systems through competitive bidding, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) solicits generic multi-source pharmaceuticals and over-the-counter products from manufacturers for distribution across member state and local government facilities. The Texas Health and Human Services Commission has issued an exploratory RFI to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The issuing bodies span county health departments, state health agencies, and cooperative purchasing alliances serving multiple jurisdictions. Recent procurement activity reflects state and local demand for pharmaceutical inventory, naloxone for community health initiatives, generic medications for institutional use, and alternative pharmacy distribution models.

Recent opportunities show concentration in Florida and the upper Midwest with national reach through cooperative purchasing. Seminole County's IFB60459723LAS sought 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. MMCAP's Request for Proposal S1070000015802, posted January 20, 2026 with a response deadline of March 26, 2026, established contracts for generic pharmaceuticals and OTC products to be distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson) with awards effective July 1, 2026 and a two-year initial term. The Texas HHS RFI HHS0017013, posted April 3, 2026, represents preliminary market research into direct manufacturer relationships and does not indicate an imminent formal procurement. Vendors pursuing this code should expect requirements for cGMP and Drug Supply Chain Security Act compliance, comprehensive insurance coverage, electronic ordering capability, and E-Verify verification; cooperative purchasing vehicles like MMCAP offer access to multiple state and local buyers through a single contract mechanism.